Study of Obesity Control by Astragalus and Notoginseng Extrats

Not Applicable

Completed

• Conditions: Obesity
• Interventions: Dietary Supplement: Placebo; Dietary Supplement: InnoSlim

• Registration Number: NCT03654391
• Lead Sponsor: Chung Shan Medical University

Brief Summary

The effects of the Astragalus and Notoginseng extrats on obesity control was demonstrated in a randomized double-blind, and crossover human trial.

Detailed Description

Obesity refers to the body due to physiological or biochemical function of the change caused by excessive accumulation of body fat, resulting in weight gain. Hence, the aim of this study was to evaluate the effects of the Astragalus and Notoginseng extrats on obesity control by a randomized double-blind and crossover human trial. Subjects with simple obesity (body mass index (BMI) ≥ 27 or body fat ≥ 30%) ingested 5 extrats (n = 19) capsules or placebo (n = 19) perday for 12 weeks of a stage. Anthropometric measurements (body weight, body fat, blood pressure) and blood biochemical markers including fasting blood glucose (FBG), albumin, total cholesterol (TC), triglyceride (TG), HDL-C, LDL-C, creatinine (Cr), blood urea nitrogen (BUN), AST, ALT were examined every six weeks.

Study Timeline

• Study Start: 2016-10
• Primary Completion: 2017-08
• Study Completion: 2017-10
• Study First Submitted: 2018-08-29
• Study First Submitted QC: 2018-08-29
• Study First Posted: 2018-08-31
• Status Verified: 2019-12
• Last Update Submitted: 2019-12-13
• Last Update Posted: 2019-12-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 38

Inclusion Criteria

• Body mass index (BMI) ≥ 27 or body fat ≥ 30%;
• No history of serious diseases associated with heart, liver, kidney, endocrine systems or other organs;
• No drugs consumption.

Exclusion Criteria

• BMI >35;
• Alcoholic;
• US-controlled diabetics;
• Stoke in past one year;
• High blood pressure;
• Mental diseases or melancholia;
• Pregency or breast-feeding a child.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Subjects ingested 2 capsules placebo (Control group) in the morning and 3 capsules in the evening (5 capsules/d) for 12 weeks of a stage.
InnoSlim	InnoSlim	Subjects ingested 2 capsules InnoSlim® (Experimental group) in the morning and 3 capsules in the evening (5 capsules/d) for 12 weeks of a stage.

Primary Outcome Measures

Name	Time	Method
The changes of body weight and BMI of the subjects.	12 weeks	values change of body weight and BMI between before to after 12 weeks

Secondary Outcome Measures

Name	Time	Method
The changes of triglyceride (TG) of the subjects	12 weeks	values change of triglyceride (TG) between before to after 12 weeks